Belov Artem , CFO
description
Transcript of Belov Artem , CFO
Belov Artem, CFO123458, Moscow, Str. Twardowski, 8/1, office 405Skype: artem.belov.mspphone : +7 (925) 859-10-85 [email protected]
The product
1. Number of tumor cells
2. Intensity of staining
Known approach of cancer tissue diagnostic
Our approach based on both known measurements +
Identify the number of antigens in each cell directly
(Efficiency is proved by Russian state pathologist burro)
Uniqueness
Microspace shows real distribution of
antigens in tumor cells
Analogues (Leica, Carl Zeiss) shows one rough parameter of antigens in
tumor cells Precise knowledge on antigens allows
development of much more efficient treatment plans
Score evaluation
+2
Antigens distribution
Microspace equipment use for developing the new approach
Market leadership through better efficiency of
cancer therapy
Microspace Team
• Experience in international projects• 30 years of medical experience• 20 years experience in development
Global market
Market size: - 190 ml. USD in 2012.- 150 thousands diagnostic systems.
Tripling of the market by 2020!
CAGR till 2018 – 23%.
Business model
Hardware – B2B segment for major DistributorSoftware – B2C, B2B segment
Advantages:-Great market potential of new approach-Unique technology and protectable IP
Main budget figures
2014 - $ 0.7 ml to launch the products in
Russia and patenting processes
Reaching breakeven point in the 2nd qr.
2015
2015 -2017 – Exit or next round for
scaling
Financials (K USD)
2014 2015 2016
Revenues 400 924 1,801
Costs 1,056 1,185 1,581
EBITDA -656 -261 220
Great opportunity of industrial take over within 2-4 yearsBy this time, Microspace will be:
- Leader of digital pathology in Russia- Pioneer of new technology wave in the global scaleMore than 10 comparable takeovers
THANK YOU FOR ATTENTION
123458, Moscow, Str. Twardowski, 8/1, office 405Skype: artem.belov.mspphone: +7 (925) [email protected]
Artem Belov, CFO